ReportsnReports – Market and Product Forecasts: Top 20 Oncology Therapy Brands – The value of the top 20 decreases as the oncology market fragments
Upcoming SlideShare
Loading in...5
×
 

ReportsnReports – Market and Product Forecasts: Top 20 Oncology Therapy Brands – The value of the top 20 decreases as the oncology market fragments

on

  • 467 views

The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. However, the shift toward a more personalized approach ...

The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. However, the shift toward a more personalized approach means fewer drugs will achieve blockbuster status. The evolution of a fragmented oncology market will decrease the value of the top 20 branded therapies by $8.6 billion between 2010 and 2020.

Statistics

Views

Total Views
467
Views on SlideShare
467
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

ReportsnReports – Market and Product Forecasts: Top 20 Oncology Therapy Brands – The value of the top 20 decreases as the oncology market fragments ReportsnReports – Market and Product Forecasts: Top 20 Oncology Therapy Brands – The value of the top 20 decreases as the oncology market fragments Document Transcript

  • Market and Product Forecasts: Top 20 Oncology Therapy Brands – The value of the top 20 decreases as the oncology market fragments ReportsnReports.com adds NanoMarkets Datamonitor Research Report “Market and Product Forecasts: Top 20 Oncology Therapy Brands – The value of the top 20 decreases as the oncology market fragments’’ to its store. The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. However, the shift toward a more personalized approach means fewer drugs will achieve blockbuster status. The evolution of a fragmented oncology market will decrease the value of the top 20 branded therapies by $8.6 billion between 2010 and 2020. Oncology Therapy Brands market Oncology Therapy Brands products Oncology Therapy Brands forecasts Features and benefits In depth analysis of the factors influencing the top 20 oncology brands in individual countries of the seven major markets Sales forecasts for the top 20 cancer therapy brands from 2010 to 2020. Brand dynamics and assessment of the top 5 cancer brands in the seven major markets The report is accompanied by a PowerPoint presentation and Excel deliverable showing full top 20 forecasts for the US, Japan and 5EU. Highlights In 2020, targeted therapies will dominate the top 20, but as developers focus on niche subsets of patients with specific genetic mutations the market will fragment. As a result, the total sales of the top 20 branded therapies in the seven major markets will decrease from $36.6 billion in 2010 to just over $28 billion in 2020. Generic erosion of multiple key brands in the cytotoxic class will be the key driver in decreasing its share of the top 20 branded sales in the seven major markets from 21% in 2010 to 3% in 2020. However, differing brand loyalty means patent expiries will have varying effects on the top 20 in individual markets. Roche dominated the top 20 in 2010, with combined seven major market sales of $13.2 billion. Avastin, Rituxan, and Herceptin look set to maintain the top three positions in 2020 and Roche looks set to consolidate its leading position in the oncology market. Table Of Contents OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus
  • Datamonitor key findingsRelated reportsMARKET DEFINITIONMarket definition for cancer therapiesAntihormonal therapies by ATC classCytotoxic therapies by ATC classTargeted therapies by ATC classForecast methodology and assumptionsMethodology flowPatent expiriesAdditional forecast methodologyMARKET OVERVIEW AND CONTEXTCancer therapy brands included in this reportSeven major market top 20 oncology therapy brandsThe top 20 across the seven major markets will be dominated by targeted therapies by2020US top 20 oncology therapy brandsThe US top 20 will fragment as more targeted therapies enter the marketJapan top 20 oncology therapy brandsPatent expiries will have a lower impact on the Japanese top 20Five major EU markets top 20 oncology therapy brandsBranded drugs will resist generic erosion leading to smaller changes in the top 20France top 20 oncology therapy brandsFrance maintains the largest top 20 market in the five major EU markets over the forecastperiodGermany top 20 oncology therapy brandsPrice cuts and high generic erosion will decrease the size of Germany’s top 20 brandsItaly top 20 oncology therapy brandsBrand loyalty will maintain the majority of the top 20Spain top 20 oncology therapy brandsPrice cuts will limit the growth of targeted therapies in the top 20UK top 20 oncology therapy brandsThe UK’s strict cost-effective reimbursement policy will continue to limit sales of the top 20brandsPRODUCT FORECASTSBrand dynamicsRoche’s monoclonal antibody franchise will comprise the top three in 2010 and 2020Avastin (bevacizumab; Genentech/Roche/Chugai)Forecast assumptionsAvastin forecast 2010–20Rituxan (rituximab; Biogen Idec/Genentech/Roche/Chugai)Forecast assumptionsRituxan forecast 2010–20Herceptin (trastuzumab; Genentech/Roche/Chugai)Forecast assumptionsHerceptin forecast 2010–20
  • Gleevec/Glivec (imatinib; Novartis)Forecast assumptionsGleevec forecast 2010–20Taxotere (docetaxel; Sanofi)Forecast assumptionsTaxotere forecast 2010–20Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)Forecast assumptionsErbitux forecast 2010–20Revlimid (lenalidomide; Celgene)Forecast assumptionsRevlimid forecast 2010–20BIBLIOGRAPHYJournal papersWebsitesDatamonitor reportsAPPENDIXForecast methodologyVolume and value forecast methodologyPrice assumptionsReport methodologyLIST OF TABLESTable: Definition of the cancer market, 2011Table: Patent expiry dates for antihormonal therapies in the top 20, 2010–20Table: Patent expiry dates for cytotoxic therapies in the top 20, 2010–20Table: Patent expiry dates for targeted therapies in the top 20, 2010–20Table: Drugs included in the top 20 cancer therapy brands, 2010–20Table: Sales of the top 20 cancer therapy brands in the seven major markets, 2010Table: Forecast sales of the top 20 cancer therapy brands in the seven major markets ($m),2010–20Table: Sales of the top 20 cancer therapy brands in the US, 2010Table: Forecast sales of the top 20 cancer therapy brands in the US ($m), 2010–20Table: Sales of the top 20 cancer therapy brands in Japan, 2010Table: Forecast sales of the top 20 cancer therapy brands in Japan ($m), 2010–20Table: Sales of the top 20 cancer therapy brands in the five major EU markets, 2010Table: Forecast sales of the top 20 cancer therapy brands in the five major EU markets($m), 2010–20Table: Sales of the top 20 cancer therapy brands in France, 2010Table: Forecast sales of top 20 cancer therapy brands in France ($m), 2010–20Table: Sales of the top 20 cancer therapy brands in Germany, 2010Table: Forecast sales of top 20 cancer therapy brands in Germany ($m), 2010–20Table: Sales of the top 20 cancer therapy brands in Italy, 2010Table: Forecast sales of top 20 cancer therapy brands in Italy ($m), 2010–20Table: Sales of the top 20 cancer therapy brands in Spain, 2010Table: Forecast sales of top 20 cancer therapy brands in Spain ($m), 2010–20Table: Sales of the top 20 cancer therapy brands in the UK, 2010
  • Table: Forecast sales of top 20 cancer therapy brands in the UK ($m), 2010–20Table: Key branded cancer therapy sales in the seven major markets, 2010 and 2020Table: Avastin sales, by country ($m), 2010–20Table: Rituxan sales, by country ($m), 2010–20Table: Herceptin sales, by country ($m), 2010–20Table: Gleevec sales, by country ($m), 2010–20Table: Taxotere sales, by country ($m), 2010–20Table: Erbitux sales, by country ($m), 2010–20Table: Revlimid sales, by country ($m), 2010–20LIST OF FIGURESFigure: Company-reported sales-based forecast methodology, 2011Figure: Unevented and evented company-reported sales-based forecast, 2011Figure: Sales of the top 20 cancer therapy brands in the seven major markets, by drug class($m), 2010 and 2020Figure: Sales of the top 20 cancer therapy brands in the US, by drug class ($m), 2010 and2020Figure: Sales of the top 20 cancer therapy brands in Japan, by drug class ($m), 2010 and2020Figure: Sales of the top 20 cancer therapy brands in the five major EU markets by drugclass ($m), 2010 and 2020Figure: Sales of the top 20 cancer therapy brands in France, by drug class ($m), 2010 and2020Figure: Sales of the top 20 cancer therapy brands in Germany, by drug class ($m), 2010and 2020Figure: Sales of the top 20 cancer therapy brands in Italy, by drug class ($m), 2010 and2020Figure: Sales of the top 20 cancer therapy brands in Spain, by drug class ($m), 2010 and2020Figure: Sales of the top 20 cancer therapy brands in the UK by drug class ($m), 2010 and2020Figure: Key branded drug sales, 2010–20Figure: Avastin sales, by country ($m), 2010–20Figure: Rituxan sales by country, ($m), 2010-20Figure: Herceptin sales, by country ($m), 2010–20Figure: Gleevec sales, by country ($m), 2010–20Figure: Taxotere sales, by country ($m), 2010–20Figure: Erbitux sales, by country ($m), 2010–20Figure: Revlimid sales, by country ($m), 2010–20Latest Market Research Reports: Epidemiology: Hypertension – Rising with increasing obesity and population growth The Markets for Flexible Glass – 2011 Molybdenum Markets in the Electronics and Solar Industries -2011 Food Market Research Bundle: Fats and Oils Home Organization in the U.S.: General Purpose, Closets, Garages, and Storage Sheds, 2nd Edition The Global Market for Distributed Energy Generation
  • About Us:ReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr. Priyank7557 Rambler road,Suite 727, Dallas, TX 75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit Our Blog : Market Research Reports